TABLE 2.
Assessment of screening criteria and cost savings according to viral etiologya
| Criteria used | HSV-1/2 |
VZV |
CMV |
EV |
EV (April to October) |
Total |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive tests accepted | Negative tests cancelled | Positive tests accepted | Negative tests cancelled | Positive tests accepted | Negative tests cancelled | Positive tests accepted | Negative tests cancelled | Positive tests accepted | Negative tests cancelled | Positive tests accepted | Negative tests cancelled | |
| Total no. | 56 | 112 | 27 | 54 | 20 | 40 | 20 | 40 | 123 | 246 | ||
| No. with cell counts | 55 | 112 | 27 | 54 | 20 | 39 | 20 | 39 | 122 | 244 | ||
| No. with protein levels | 56 | 112 | 26 | 54 | 19 | 40 | 20 | 39 | 121 | 245 | ||
| WBC count of >5 cells/μl or protein level of >50 mg/dl (% [no./total no.]) | 91 (50/55) | 55 (62/112) | 88 (23/26) | 41 (22/54) | 68 (13/19) | 21 (8/39) | 100 (20/20) | 33 (13/39) | 95 (19/20) | 80 (32/40) | 88 (106/120) | 50 (123/244) |
| WBC count of >5 cells/μl (% [no./total no.]) | 85 (47/55) | 77 (86/112) | 78 (21/27) | 63 (34/54) | 25 (5/20) | 51 (20/39) | 100 (20/20) | 49 (19/39) | 95 (19/20) | 65 (26/40) | 76 (93/122) | 59 (144/244) |
| WBC count of >10 cells/μl (% [no./total no.]) | 85 (47/55) | 83 (93/112) | 67 (18/27) | 69 (37/54) | 25 (5/20) | 74 (29/39) | 95 (19/20) | 64 (25/39) | 90 (18/20) | 75 (30/40) | 73 (89/122) | 66 (160/244) |
| WBC count of >5 cells/μl or protein level of >50 mg/dl or immunosuppressed (16) (% [no./total no.]) | 95 (52/55) | 46 (52/112) | 96 (25/26) | 33 (18/54) | 84 (16/19) | 26 (10/39) | 100 (20/20) | 36 (14/39) | 95 (19/20) | 58 (23/40) | 94 (113/120) | 39 (94/244) |
| WBC count of >5 cells/μl or immunosuppressed (% [no./total no.]) | 95 (52/55) | 58 (65/112) | 96 (26/27) | 48 (26/54) | 80 (16/20) | 28 (11/39) | 100 (20/20) | 38 (15/39) | 95 (19/20) | 60 (24/40) | 93 (114/122) | 48 (117/244) |
| WBC count of >10 cells/μl or immunosuppressed (17) (% [no./total no.]) | 95 (52/55) | 63 (71/112) | 96 (26/27) | 50 (27/54) | 80 (16/20) | 44 (17/39) | 100 (20/20) | 51 (20/39) | 95 (19/20) | 68 (26/40) | 93 (114/122) | 55 (135/244) |
| Optimal algorithm (% [no./total no.]) | 93 (113/122) | 58 (141/244) | ||||||||||
a
Annual savings were calculated as price per test × % cancelled × total negative tests/5-year time period. The calculated savings were as follows: HSV-1/2, $38,907; VZV, $10,100; CMV, $7,942; EV (April to October), $8,041; total, $64,989.